Patient-reported cognitive function before and after glioma surgery.
Brain neoplasms
Cognition
Glioma
Neurosurgery
Patient-reported outcome measures
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
01
03
2022
accepted:
21
05
2022
pubmed:
7
6
2022
medline:
3
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Little is known about the extent to which glioma patients experience subjective changes in cognitive function following surgery. We sought to assess patient-reported cognitive function before and after glioma surgery and explore potential factors associated with cognitive change. In a prospective population-based study, patient-reported cognitive function was measured in 182 patients undergoing primary surgery for diffuse glioma (141 high-grade gliomas (HGG) and 41 low-grade gliomas (LGG)) by using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cognitive function subscale preoperatively and at 1 and 6 months postoperatively. Binomial logistic regression models were used to assess factors possibly associated with patient-reported cognitive changes. In the HGG group, the mean cognitive function score increased from 70.9 (95% 66.6, 75.2) preoperatively to 85.1 (95% CI 81.2, 89.0) (p < 0.001) and 83.3 (95% CI 79.1, 87.6) (p < 0.001) at 1 and 6 months postoperatively, respectively. In the LGG group, the mean score was 80.9 (95% CI 74.4, 87.4) preoperatively and remained stable at postoperative follow-ups. Females reported lower scores than males. At an individual level, both improvement and deterioration in cognitive scores were frequently seen in LGG and HGG patients after surgery. Preoperative use of corticosteroids and large tumor volume were predictors for cognitive improvement at 1 month postoperatively. No predictors were identified for cognitive improvement at 6 months and worsening at 1 and 6 months. Many glioma patients experience perioperative subjective changes in cognitive function after surgery. At group level, HGG patients reported improved cognitive function after surgery, while LGG patients reported stable cognitive function. Preoperative use of corticosteroids and large tumor volume were independently associated with postoperative improvement.
Sections du résumé
BACKGROUND
Little is known about the extent to which glioma patients experience subjective changes in cognitive function following surgery. We sought to assess patient-reported cognitive function before and after glioma surgery and explore potential factors associated with cognitive change.
METHODS
In a prospective population-based study, patient-reported cognitive function was measured in 182 patients undergoing primary surgery for diffuse glioma (141 high-grade gliomas (HGG) and 41 low-grade gliomas (LGG)) by using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cognitive function subscale preoperatively and at 1 and 6 months postoperatively. Binomial logistic regression models were used to assess factors possibly associated with patient-reported cognitive changes.
RESULTS
In the HGG group, the mean cognitive function score increased from 70.9 (95% 66.6, 75.2) preoperatively to 85.1 (95% CI 81.2, 89.0) (p < 0.001) and 83.3 (95% CI 79.1, 87.6) (p < 0.001) at 1 and 6 months postoperatively, respectively. In the LGG group, the mean score was 80.9 (95% CI 74.4, 87.4) preoperatively and remained stable at postoperative follow-ups. Females reported lower scores than males. At an individual level, both improvement and deterioration in cognitive scores were frequently seen in LGG and HGG patients after surgery. Preoperative use of corticosteroids and large tumor volume were predictors for cognitive improvement at 1 month postoperatively. No predictors were identified for cognitive improvement at 6 months and worsening at 1 and 6 months.
CONCLUSION
Many glioma patients experience perioperative subjective changes in cognitive function after surgery. At group level, HGG patients reported improved cognitive function after surgery, while LGG patients reported stable cognitive function. Preoperative use of corticosteroids and large tumor volume were independently associated with postoperative improvement.
Identifiants
pubmed: 35668303
doi: 10.1007/s00701-022-05261-3
pii: 10.1007/s00701-022-05261-3
pmc: PMC9338128
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2009-2019Informations de copyright
© 2022. The Author(s).
Références
Neurooncol Pract. 2017 Dec;4(4):229-240
pubmed: 31386003
Acta Neurochir (Wien). 2022 Mar;164(3):703-711
pubmed: 35142918
Cancer. 1984 May 1;53(9):2002-7
pubmed: 6704925
Neurooncol Pract. 2014 Jun;1(2):40-46
pubmed: 26034615
Acta Neurochir (Wien). 2017 Feb;159(2):377-384
pubmed: 27928631
Neuropsychol Rev. 2003 Dec;13(4):181-97
pubmed: 15000225
Am Sociol Rev. 1969 Feb;34(1):58-72
pubmed: 5776179
Neurosurg Focus. 2018 Jun;44(6):E17
pubmed: 29852767
J Neurooncol. 2019 Jan;141(1):167-182
pubmed: 30446902
J Neurooncol. 2017 Aug;134(1):9-18
pubmed: 28567586
Neuro Oncol. 2012 Jun;14(6):808-16
pubmed: 22508762
Soc Sci Med. 1999 Jun;48(11):1507-15
pubmed: 10400253
J Neurooncol. 2019 May;143(1):175-176
pubmed: 30859484
Lancet Oncol. 2020 Feb;21(2):e97-e103
pubmed: 32007210
Curr Oncol Rep. 2020 Sep 23;22(12):120
pubmed: 32965568
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
J Clin Oncol. 2011 Nov 20;29(33):4430-5
pubmed: 22010018
J Clin Oncol. 2017 Jul 20;35(21):2439-2449
pubmed: 28640707
J Neurooncol. 2007 Feb;81(3):305-13
pubmed: 16944311
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet Oncol. 2016 Nov;17(11):1533-1542
pubmed: 27686943
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Clin Neurol Neurosurg. 2021 Nov;210:106953
pubmed: 34607197
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Front Oncol. 2019 Aug 20;9:783
pubmed: 31482068
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
Neuro Oncol. 2016 Dec;18(12):1656-1663
pubmed: 27576872
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
J Neurol. 2021 Apr;268(4):1434-1442
pubmed: 33211158
Neurooncol Adv. 2021 Feb 26;3(1):vdab008
pubmed: 33665615
Eur J Cancer. 2021 Feb;144:162-168
pubmed: 33348088
Neurooncol Pract. 2015 Mar;2(1):20-31
pubmed: 26034638
J Nurs Scholarsh. 2007;39(1):61-7
pubmed: 17393967
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Clin Neurol Neurosurg. 2017 Dec;163:18-23
pubmed: 29035741
J Cancer Surviv. 2019 Oct;13(5):653-662
pubmed: 31313128
J Neurooncol. 2011 Jul;103(3):541-9
pubmed: 20878206
Acta Neurochir (Wien). 2014 Aug;156(8):1451-9
pubmed: 24879620
J Neurooncol. 2020 Sep;149(3):403-411
pubmed: 32960402
Langenbecks Arch Surg. 2016 Jun;401(4):541-9
pubmed: 27030244
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
World Neurosurg. 2011 May-Jun;75(5-6):709-15; discussion 604-11
pubmed: 21704941
Ann Oncol. 2011 Sep;22(9):2107-2112
pubmed: 21324954